Document:

EXHIBIT 10.2 

 

NRX Pharmaceuticals,
Inc.

March 9, 2022

 

Robert Besthof

 

Dear Robert,

 

This letter agreement (the
“Agreement”) supplements the Work for Hire Agreement entered into by and between REBes Consulting LLC- Robert Besthof
(“Consultant”) and NeuroRx, Inc., dated March 1, 2016 as amended on October 23, 2020 (the “Consulting Agreement”).
The purpose of this Agreement is to confirm your appointment as the Interim Chief Executive Officer of NRX
Pharmaceuticals, Inc. (the “Company”) beginning on the March 8, 2022 (the “Effective Date”).
While providing services as Interim Chief Executive Officer, you will continue to be provide services pursuant to the Consulting Agreement
and you will also continue to serve as the Chief Commercial and Patient Officer and Head of Operations. Any capitalized terms used in
this Agreement without definition will have the same meaning as in the Consulting Agreement.

We appreciate your willingness
to serve as Interim Chief Executive Officer and you will be considered for appointment as our Chief Executive Officer on a permanent basis.
If you are appointed as our permanent Chief Executive Officer, we will revisit your compensation arrangements and anticipate that we will
enter a new employment agreement or consulting agreement on terms to be mutually agreed upon.

While you are providing
services under this Agreement as Interim Chief Executive Officer, you will report to the Board of Directors of the Company (the “Board”)
and will do and perform all reasonable services, acts or things necessary or advisable to manage and conduct the business of the Company
and that are normally associated with the position of principal executive officer, consistent with the bylaws of the Company and as required
by the Board. During the term of your service, you will devote your full business energies, interest, abilities, and productive time to
the proper and efficient performance of your duties under this Agreement, and you will not, without the prior written consent of the Board,
engage in any other business activity that would materially interfere with the performance of your duties under this Agreement.

In connection with your
appointment as Interim Chief Executive Officer, we are pleased to offer you the following payments (in addition to your current compensation):

		1.	Your current base payment will remain $22,000.00 (twenty two thousand dollars) per month.

 

		2.	You will receive an additional monthly payment of $19,667.00 (nineteen thousand six hundred sixty seven
dollars) beginning on the Effective Date for total annual payments at a rate of approximately $500,000, and this additional payment will
continue in effect for as long as you serve as Interim Chief Executive Officer. It is acknowledged that you will receive

     

     

    

 

	 	 	the additional payments for at least six
months after the Effective Date (equal to $118,000 in the aggregate) unless you voluntarily resign or your services are terminated for
Cause (as defined below).
	 	 	 
		3.	You will be eligible to receive a special payment for calendar year 2022 equal to $250,000 at target,
based on achievement of performance metrics to be determined by the Board, and, except as otherwise provided in this Agreement, such special
payment to the extent earned shall be paid on or before March 15, 2023.

 

		4.	Effective on the Effective Date, the Board has approved a grant of options to purchase 100,000 shares
of the Company’s common stock in connection with your provision of services as the Interim Chief Executive Officer. The options
are be subject to the Company’s 2021 Omnibus Incentive Plan and applicable award agreement, have an exercise price equal to the
fair market value of the Company’s common stock on the date of such Board approval and such options shall vest on the first anniversary
of the Effective Date, subject to your continued service with the Company, provided that if you are not appointed as permanent Chief Executive
Officer (“CEO”), or if your services are terminated by the Company without Cause, all unvested options shall vest in full.
Such options, to the extent vested, shall remain exercisable until the earlier of (i) the third anniversary of your cessation of service
and (ii) 10th anniversary of the Effective Date, provided that if you are terminated for Cause then such options shall cease
to be exercisable as of such termination.

 

		5.	You agree that the Company may initiate a search for a permanent CEO other than you at any time (“CEO
Search”), and you agree that the initiation of a CEO Search will not by itself constitute a breach or give you grounds to resign
your provision of services under the Consulting Agreement or because you are not appointed as the permanent Chief Executive Officer (or
because you are no longer receiving the increased payment provided for in this Agreement).

 

		6.	If in connection with the CEO Search you are not appointed as the permanent CEO, then the Company agrees
to negotiate with you in good faith to offer you a new consulting agreement or employment agreement which is at least (i) commensurate
with your current position as “Head of Operations/ Chief Commercial Officer” (it being acknowledged and agreed that this may
be equivalent in title to those of a Senior Vice President in a large pharmaceutical company and that your title may change) and (ii)
comparable base payment (but excluding the additional payment as Interim CEO) and bonus, if any (the “Comparable Terms”).
If the new CEO does not offer you Comparable Terms, as determined by the Board, then you shall be permitted to resign from your positions
with the Company (including under the Consulting Agreement) and upon such

     

     

    

 

	 	 	resignation the Company will provide you
with a separation payment of $22,000 per month payable over six months ($132,000 in the aggregate) the stock options granted under this
Agreement shall vest, and the Company will pay you the unpaid portion of the $250,000 special payment at the full target amount to the
extent the target special payment for 2022 has not been paid (the “2022 Payment Balance”). If the new CEO and the Board do
not offer you Comparable Terms, then prior to your resignation under this Section 6 (x) you must provide the Company with written notice
of your intent to resign specifying this provision within 30 days after the date you were not offered Comparable Terms, and (y) such resignation
shall not occur until 90 days after the date of such notice (or such earlier date as agreed by the Company in its sole discretion).
	 	 	 
		7.	If prior to the hiring on a permanent CEO, your provision of services as interim CEO under this Agreement
is terminated by the Company without Cause (and not as a result of your voluntary resignation), then you will receive separation payments
of (i) $41,667 per month payable for six months, and (ii) the 2022 Payment Balance and (iii) your unvested options under this Agreement
shall vest.

 

		8.	For the avoidance of doubt, in no event will you receive the separation payments under both Section 6
and Section 7 of this Agreement, and to the extent that you receive separation payments under Section 6 or 7, then you shall not be entitled
to receive separation payments under the Consulting Agreement. As a condition to the receipt of separation payments under this Agreement
and the extended exercisability of the options under Section 4 of this Agreement, you will be required to execute a release of claims
in favor of the Company within 30 days after the date of such termination in a form provided by the Company.

 

		9.	You shall be added as a named insured under the Company’s directors’ and officers’ insurance
policy and you shall be indemnified to the same extent as all other executive officers of the Company with respect to all claims arising
for periods before your termination of service.

 

		10.	“Cause” shall mean (i) your gross negligence or willful misconduct, or willful and continued
failure to substantially perform your duties (other than due to physical or mental illness or incapacity), which, in either case, causes
material injury to the reputation or business of the Company, (ii) your conviction of, or plea of guilty or nolo contendere to, a
felony or other crime, (iii) your fraud or embezzlement or other material misuse of funds or property belonging to the Company, or (iv)
any material breach by you of any of the Company’s rules, policies and procedures or a material breach by you of the Consulting
Agreement, subject to a ten day notice and cure period (if reasonably capable of prompt cure); provided

     

     

    

 

	 	 	that any determination for Cause under this
Section 9 shall be made by the Board in its good faith judgment.
	 	 	 
		11.	For the avoidance of doubt, you shall continue to provide your services as an independent contractor and
not as an employee as set forth in Section 3 of the Consulting Agreement.

 

This Agreement and the
rights hereunder may not be modified, amended, assigned or transferred, in whole or in part, except in a formal, definitive written agreement
expressly referring hereto, which agreement is signed by an authorized officer of the Company and by you.

 

 

 

 

[Remainder of the page left intentionally blank.]

     

     

    

 

We look forward to you assuming leadership of the Company and to
continuing to work together to grow the value of the Company.

 

NRX Pharmaceuticals,
Inc.

 

	By:	/s/ Alessandra Daigneault	 
	Print Name: Alessandra Daigneault
	Its: Chief Corporate Officer, General Counsel, Secretary & Acting Treasurer
	 	 	 
	Accepted And Agreed:	 
	 	 	 
	Consultant	 
	 	 	 
	/s/ Robert Besthof	 
	Name: Robert Besthof	 
	REBES Consulting LLC	 

 

 

 

 

[Signature page to the REBes Consulting LLC
Letter Agreement]EX-10.6

   

  Exhibit 10.6

   

  MIRUM PHARMACEUTICALS, INC.

   

  STANDARD STOCK OPTION GRANT NOTICE - INTERNATIONAL 

  (2019 EQUITY INCENTIVE PLAN) 

   

  Mirum Pharmaceuticals, Inc. (the "Company"), pursuant to its 2019 Equity Incentive Plan (the "Plan"), hereby grants to Optionholder an option to purchase the number of shares of the Company's Common Stock set forth below.  This option is subject to all of the terms and conditions as set forth in this Stock Option Grant Notice, in the Option Agreement, the Plan and the Notice of Exercise, all of which are attached hereto and incorporated herein in their entirety, including any special terms and conditions for the Optionholder's country set forth in the attached appendix (the "Appendix").  Capitalized terms not explicitly defined herein but defined in the Plan or the Option Agreement will have the same definitions as in the Plan or the Option Agreement. If there is any conflict between the terms in this Stock Option Grant Notice and the Plan, the terms of the Plan will control. 

   

  		
	Optionholder:
	 

	Date of Grant:
	 

	Vesting Commencement Date:
	 

	Number of Shares Subject to Option:
	 

	Exercise Price (Per Share): 
	 

	Total Exercise Price:
	 

	Expiration Date:
	 

   

  		
	Type of Grant:
	Nonstatutory Stock Option

	 
	 

	Exercise Schedule:
	[Same as Vesting Schedule]

   

  		
	Vesting Schedule:
	[______________, subject to Optionholder’s Continuous Service as of each such date.]

	 
	 

	Payment:
	By one or a combination of the following items (described in the Option Agreement):

	 
	☐ By cash, check, bank draft or money order payable to the Company

	 
	☐ Pursuant to a Regulation T Program if the shares are publicly traded

	 
	☐ By delivery of already-owned shares if the shares are publicly traded

	 
	☐ Subject to the Company’s consent at the time of exercise, by a “net exercise” arrangement

   

  Additional Terms/Acknowledgements:  Optionholder acknowledges receipt of, and understands and agrees to, this Stock Option Grant Notice, the Option Agreement (including the Appendix) and the Plan. Optionholder acknowledges and agrees that this Stock Option Grant Notice and the Option Agreement (including the Appendix) may not be modified, amended or revised except as provided in the Plan. Optionholder further acknowledges that as of the Date of Grant, this Stock Option Grant Notice, the Option Agreement (including the Appendix), and the Plan set forth the entire understanding between Optionholder and the Company regarding this option award and supersede all prior oral and written agreements, promises and/or representations on that subject with the exception of, if applicable, (i) equity awards previously granted and delivered to Optionholder, (ii) any compensation recovery policy that is adopted by the Company or is otherwise required by applicable law and (iii) any written employment agreement, severance agreement, offer letter or other written agreement entered into between the Company and Participant 

  1

  

   

  specifying the terms that should govern this specific option.  By accepting this option, Optionholder consents to receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company. 

   

  						
	MIRUM PHARMACEUTICALS, INC.
	  
	  
	Optionholder:

	  
	  
	  
	  
	  
	  

	By:
	  
	  
	  
	  

	  
	Signature
	  
	  
	  
	Signature

	Title:
	  
	  
	  
	Date:
	  

	Date:
	  
	  
	  
	  
	  

   

  ATTACHMENTS:  Option Agreement (including the Appendix), 2019 Equity Incentive Plan and Notice of Exercise 

  2

  

   

  ATTACHMENT I

   

  MIRUM PHARMACEUTICALS, INC. 

  OPTION AGREEMENT - INTERNATIONAL

  (2019 EQUITY INCENTIVE PLAN) 

  (NONSTATUTORY STOCK OPTION) 

   

  Pursuant to your Stock Option Grant Notice ("Grant Notice") and this Option Agreement, including any special terms and conditions for your country set forth in the appendix attached hereto (the "Appendix") Mirum Pharmaceuticals, Inc. (the "Company") has granted you an option under its 2019 Equity Incentive Plan (the "Plan") to purchase the number of shares of the Company's Common Stock indicated in your Grant Notice at the exercise price indicated in your Grant Notice.  The option is granted to you effective as of the date of grant set forth in the Grant Notice (the "Date of Grant").  If there is any conflict between the terms in this Option Agreement and the Plan, the terms of the Plan will control. Capitalized terms not explicitly defined in this Option Agreement or in the Grant Notice but defined in the Plan will have the same definitions as in the Plan. 

   

  The details of your option, in addition to those set forth in the Grant Notice and the Plan, are as follows: 

  1.VESTING.  Subject to the provisions contained herein, your option will vest as provided in your Grant Notice.  Vesting will cease upon the termination of your Continuous Service. 

  2.NUMBER OF SHARES AND EXERCISE PRICE.  The number of shares of Common Stock subject to your option and your exercise price per share in your Grant Notice will be adjusted for Capitalization Adjustments. 

  3.METHOD OF PAYMENT.  You must pay the full amount of the exercise price for the shares you wish to exercise.  You may pay the exercise price in cash or by check, bank draft or money order payable to the Company or in any other manner permitted by your Grant Notice, which may include one or more of the following: 

  (a)Provided that at the time of exercise the Common Stock is publicly traded, pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of Common Stock, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds.  This manner of payment is also known as a "broker-assisted exercise", "same day sale", or "sell to cover". 

  (b)Provided that at the time of exercise the Common Stock is publicly traded, by delivery to the Company (either by actual delivery or attestation) of already-owned shares of Common Stock that are owned free and clear of any liens, claims, encumbrances or security interests, and that are valued at Fair Market Value on the date of exercise.  "Delivery" for these purposes, in the sole discretion of the Company at the time you exercise your option, will include delivery to the Company of your attestation of ownership of such shares of Common Stock in a form approved by the Company.  You may not exercise your option by delivery to the Company of Common Stock if doing so would violate the provisions of any law, regulation or agreement restricting the redemption of the Company's stock. 

  1

  

   

  (c)Subject to the consent of the Company at the time of exercise, by a "net exercise" arrangement pursuant to which the Company will reduce the number of shares of Common Stock issued upon exercise of your option by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price.  You must pay any remaining balance of the aggregate exercise price not satisfied by the "net exercise" in cash or other permitted form of payment.  Shares of Common Stock will no longer be outstanding under your option and will not be exercisable thereafter if those shares (i) are used to pay the exercise price pursuant to the "net exercise," (ii) are delivered to you as a result of such exercise, and (iii) are withheld to satisfy your tax and/or social security withholding obligations. 

  4.WHOLE SHARES. You may exercise your option only for whole shares of Common Stock.

  5.SECURITIES LAW COMPLIANCE. In no event may you exercise your option unless the shares of Common Stock issuable upon exercise are then registered under the Securities Act or, if not registered, the Company has determined that your exercise and the issuance of the shares would be exempt from the registration requirements of the Securities Act.  The exercise of your option also must comply with all other applicable laws and regulations governing your option, and you may not exercise your option if the Company determines that such exercise would not be in material compliance with such laws and regulations (including any restrictions on exercise required for compliance with Treas. Reg. 1.401(k)-1(d)(3), if applicable). 

  6.TERM.  You may not exercise your option before the Date of Grant or after the expiration of the option's term.  The term of your option expires, subject to the provisions of Section 5(h) of the Plan, upon the earliest of the following: 

  (a)immediately upon the termination of your Continuous Service for Cause;

  (b)three (3) months after the termination of your Continuous Service for any reason other than Cause, your Disability or your death (except as otherwise provided in Section 6(d) below); provided, however, that if during any part of such three (3) month period your option is not exercisable solely because of the condition set forth in the section above regarding "Securities Law Compliance," your option will not expire until the earlier of the Expiration Date or until it has been exercisable for an aggregate period of three (3) months after the termination of your Continuous Service; provided further, if during any part of such three (3) month period, the sale of any Common Stock received upon exercise of your option would violate the Company's insider trading policy, then your option will not expire until the earlier of the Expiration Date or until it has been exercisable for an aggregate period of three (3) months after the termination of your Continuous Service during which the sale of the Common Stock received upon exercise of your option would not be in violation of the Company's insider trading policy; 

  (c)twelve (12) months after the termination of your Continuous Service due to your Disability (except as otherwise provided in Section 6(d)) below; 

  (d)eighteen (18) months after your death if you die either during your Continuous Service or within three (3) months after your Continuous Service terminates for any reason other than Cause; 

  (e)the Expiration Date indicated in your Grant Notice; or

  (f)the day before the tenth (10th) anniversary of the Date of Grant.

  2

  

   

  7.EXERCISE.

  (a)You may exercise the vested portion of your option (and the unvested portion of your option if your Grant Notice so permits) during its term by (i) delivering a Notice of Exercise (in a form designated by the Company) or completing such other documents and/or procedures designated by the Company for exercise and (ii) paying the exercise price and any applicable withholding taxes and/or social security to the Company's Secretary, stock plan administrator, or such other person as the Company may designate, together with such additional documents as the Company may then require. 

  (b)By exercising your option you agree that, as a condition to any exercise of your option, the Company may require you to enter into an arrangement providing for the payment by you to the Company of any tax and/or social security withholding obligation of the Company arising by reason of (i) the exercise of your option, (ii) the lapse of any substantial risk of forfeiture to which the shares of Common Stock are subject at the time of exercise, or (iii) the disposition of shares of Common Stock acquired upon such exercise. 

  8.TRANSFERABILITY.  Your option is not transferable, except by will or by the laws of descent and distribution, and is exercisable during your life only by you.   

  9.OPTION NOT A SERVICE CONTRACT.  Your option is not an employment or service contract, and nothing in your option will be deemed to create in any way whatsoever any obligation on your part to continue in the employ of the Company or an Affiliate, or of the Company or an Affiliate to continue your employment.  In addition, nothing in your option will obligate the Company or an Affiliate, their respective stockholders, boards of directors, officers or employees to continue any relationship that you might have as a Director or Consultant for the Company or an Affiliate.  By accepting your option you acknowledge, understand and agree that: 

  (a)the Plan is established voluntarily by the Company, it is discretionary in nature, and may be amended, suspended or terminated by the Company at any time, to the extent permitted under the Plan; 

  (b)the grant of your option is voluntary and occasional and does not create any contractual or other right to receive future grants of options (whether on the same or different terms), or benefits in lieu of options, even if options have been granted in the past; 

  (c)your option and any shares of Common Stock acquired under the Plan on exercise of your option, and the income and value of same, are not part of normal or expected compensation for any purpose, including, without limitation, calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, holiday pay, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments; 

  (d)the future value of the shares of Common Stock underlying the option is unknown, indeterminable, and cannot be predicted with certainty; 

  (e)neither the Company nor any Affiliate shall be liable for any foreign exchange rate fluctuation between your local currency and the United States Dollar that may affect the value of your option or of any amounts due to you pursuant to the exercise of your option or the subsequent sale of any shares of Common Stock received; 

  (f)for purposes of the option, your Continuous Service will be considered terminated as of the date you are no longer actively providing services to the Company or one of its Affiliates (regardless 

  3

  

   

  of the reason for such termination and whether or not later found to be  invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and unless otherwise expressly provided in this Option Agreement or determined by the Company, (i) your right to vest in the option under the Plan, if any, and (ii) the period (if any) during which you may exercise the option after such termination of Continuous Service will terminate as of such date and in each instance will not be extended by any notice period or any period of "garden leave" or similar period mandated under employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any); and the Plan Administrator shall have the exclusive discretion to determine when you are  no longer actively providing services for purposes of the option (including whether you may  still be considered to be providing services while on a leave of absence); 

  (g)no claim or entitlement to compensation or damages shall arise from forfeiture of this option resulting from the termination of your Continuous Service (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment or service agreement, if any), and in consideration of the grant of this option to which you are otherwise not entitled, you irrevocably agree never to institute any claim against the Company or any Affiliate, waive your ability, if any, to bring any such claim, and release the Company and any Affiliate from any such claim; if, notwithstanding the foregoing, any such claim is allowed by a court of competent jurisdiction, then, by participating in the Plan, you shall be deemed irrevocably to have agreed not to pursue such claim and agree to execute any and all documents necessary to request dismissal or withdrawal of such claim. 

  10.WITHHOLDING OBLIGATIONS.

  (a)At the time you exercise your option, in whole or in part, and at any time thereafter as requested by the Company, you hereby authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for (including by means of a "same day sale" pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board to the extent permitted by the Company), any sums required to satisfy the federal, state, local and foreign tax and/or social security withholding obligations of the Company or an Affiliate, if any, which arise in connection with the exercise of your option.   

  (b)If this option is a Nonstatutory Stock Option, then upon your request and subject to approval by the Company, and compliance with any applicable legal conditions or restrictions, the Company may withhold from fully vested shares of Common Stock otherwise issuable to you upon the exercise of your option a number of whole shares of Common Stock having a Fair Market Value, determined by the Company as of the date of exercise, not in excess of the maximum amount of tax and/or social security required to be withheld by law (or such lower amount as may be necessary to avoid classification of your option as a liability for financial accounting purposes). Notwithstanding the filing of such election, shares of Common Stock shall be withheld solely from fully vested shares of Common Stock determined as of the date of exercise of your option that are otherwise issuable to you upon such exercise.  Any adverse consequences to you arising in connection with such share withholding procedure shall be your sole responsibility. 

  (c)You may not exercise your option unless the tax and/or social security withholding obligations of the Company and/or any Affiliate are satisfied.  Accordingly, you may not be able to exercise your option when desired even though your option is vested, and the Company will have no obligation to issue a certificate for such shares of Common Stock or release such shares of Common Stock from any escrow provided for herein, if applicable, unless such obligations are satisfied. 

  4

  

   

  11.TAX CONSEQUENCES. You hereby agree that the Company does not have a duty to design or administer the Plan or its other compensation programs in a manner that minimizes your tax and/or social security liabilities. You will not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from your option or your other compensation.  

  12.NOTICES.  Any notices provided for in your option or the Plan will be given in writing (including electronically) and will be deemed effectively given upon receipt or, in the case of notices delivered by mail by the Company to you, five (5) days after deposit in the national mail, postage prepaid, addressed to you at the last address you provided to the Company.  The Company may, in its sole discretion, decide to deliver any documents related to participation in the Plan and this option by electronic means or to request your consent to participate in the Plan by electronic means.  By accepting this option, you consent to receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company. 

  13.GOVERNING PLAN DOCUMENT.  Your option is subject to all the provisions of the Plan, the provisions of which are hereby made a part of your option, and is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan.  If there is any conflict between the provisions of your option and those of the Plan, the provisions of the Plan will control.  In addition, your option (and any compensation paid or shares issued under your option) is subject to recoupment in accordance with The Dodd–Frank Wall Street Reform and Consumer Protection Act and any implementing regulations thereunder, any clawback policy adopted by the Company and any compensation recovery policy otherwise required by applicable law. 

  14.OTHER DOCUMENTS.  You hereby acknowledge receipt of and the right to receive a document providing the information required by Rule 428(b)(1) promulgated under the Securities Act, which includes the Plan prospectus.  In addition, you acknowledge receipt of the Company's policy permitting certain individuals to sell shares only during certain "window" periods and the Company's insider trading policy, in effect from time to time. 

  15.EFFECT ON OTHER EMPLOYEE BENEFIT PLANS.  The value of this option will not be included as compensation, earnings, salaries, or other similar terms used when calculating your benefits under any employee benefit plan sponsored by the Company or any Affiliate, except as such plan otherwise expressly provides. The Company expressly reserves its rights to amend, modify, or terminate any of the Company's or any Affiliate's employee benefit plans. 

  16.VOTING RIGHTS.  You will not have voting or any other rights as a stockholder of the Company with respect to the shares to be issued pursuant to this option until such shares are issued to you.   Upon such issuance, you will obtain full voting and other rights as a stockholder of the Company. Nothing contained in this option, and no action taken pursuant to its provisions, will create or be construed to create a trust of any kind or a fiduciary relationship between you and the Company or any other person. 

  17.SEVERABILITY.  If all or any part of this Option Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity will not invalidate any portion of this Option Agreement or the Plan not declared to be unlawful or invalid.  Any Section of this Option Agreement (or part of such a Section) so declared to be unlawful or invalid shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid. 

  5

  

   

  18.MISCELLANEOUS.

  (a)The rights and obligations of the Company under your option will be transferable to any one or more persons or entities, and all covenants and agreements hereunder will inure to the benefit of, and be enforceable by the Company's successors and assigns.  

  (b)You agree upon request to execute any further documents or instruments necessary or desirable in the sole determination of the Company to carry out the purposes or intent of your option. 

  (c)You acknowledge and agree that you have reviewed your option in its entirety, have had an opportunity to obtain the advice of counsel prior to executing and accepting your option, and fully understand all provisions of your option. 

  (d)This Option Agreement will be subject to all applicable laws, rules, and regulations, and to such approvals by any governmental agencies or national securities exchanges as may be required. 

  (e)All obligations of the Company under the Plan and this Option Agreement will be binding on any successor to the Company, whether the existence of such successor is the result of a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially all of the business and/or assets of the Company. 

  19.PERSONAL DATA.  The Company will collect and process information relating to you in accordance with the privacy notice from time to time in force. 

  20.LANGUAGE. If you have received this Agreement, or any other document related to this Option and/or the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control. 

  21.INSIDER TRADING/MARKET ABUSE. You acknowledge that, depending on your country, you may be subject to insider trading restrictions and/or market abuse laws, which may affect your ability to acquire or sell the shares of Common Stock or rights to the shares of Common Stock under the Plan during such times as you are considered to have "inside information" regarding the Company (as defined by the laws in your country). Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. You acknowledge that it is your responsibility to comply with any applicable restrictions, and you are advised to speak to your personal advisor on this matter. 

  22.FOREIGN ASSET/ACCOUNT, EXCHANGE CONTROL AND TAX REPORTING. You may be subject to foreign asset/account, exchange control and/or tax reporting requirements as a result of the acquisition, holding and/or transfer of shares of Common Stock or cash (including dividends and the proceeds arising from the sale of shares of Common Stock) derived from your participation in the Plan in, to and/or from a brokerage/bank account or legal entity located outside your country. The applicable laws in your country may require that you report such accounts, assets and balances therein, the value thereof and/or the transactions related thereto to the applicable authorities in such country. You may also be required to repatriate sale proceeds or other funds received as a result of your participation in the Plan to your country through a designated bank or broker within a certain time after receipt. You acknowledge that it is your responsibility to be compliant with such regulations and you are encouraged to consult with your personal legal advisor for any details. 

  6

  

   

  23.IMPOSITION OF OTHER REQUIREMENTS. The Company reserves the right to impose other requirements on your participation in the Plan, and on any shares of Common Stock acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require you to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing. 

  24.APPENDIX. Notwithstanding any provisions in this Option Agreement, your Option shall be subject to the special terms and conditions for your country set forth in the Appendix attached hereto. Moreover, if you relocate to one of the countries included therein, the terms and conditions for such country will apply to you to the extent the Company determines that the application of such terms and conditions is necessary or advisable for legal or administrative reasons. The Appendix constitutes part of this Option Agreement. 

   

  *            *            *

   

  This Option Agreement (including the Appendix) will be deemed to be signed by you upon the signing by you of the Stock Option Grant Notice to which it is attached.  

  7

  

   

  Appendix

   

  This Appendix includes special terms and conditions that govern the Option granted to you under the Plan if you reside and/or work in any country listed below. 

   

  The information contained herein is general in nature and may not apply to your particular situation, and you are advised to seek appropriate professional advice as to how the relevant laws in your country may apply to your situation. 

   

  SWITZERLAND

   

  Language Acknowledgement.

   

  You confirm having read and understood the documents relating to the Plan, including the Option Agreement, with all terms and conditions included therein, which were provided in the English language only. You confirm that you have sufficient language capabilities to understand these terms and conditions in full. 

   

  Du bestätigst, dass du den Plan sowie die dazugehörigen Dokumente, inklusive der Vereinbarung, mit all den darin enthaltenen Bedingungen und Voraussetzungen, welche in englischer Sprache verfasst sind, gelesen und verstanden hast. Du bestätigst, dass Deine Sprachkenntnisse genügend sind, um diese Bedingungen und Voraussetzungen vollumfänglich zu verstehen. 

   

  Securities Law Information.

   

  YOU ACKNOWLEDGE THAT THE PLAN IS NOT INTENDED TO BE PUBLICLY OFFERED IN OR FROM SWITZERLAND. NEITHER THE AGREEMENT NOR ANY OTHER MATERIALS RELATING TO THE OPTION CONSTITUTES A PROSPECTUS AS SUCH TERM IS UNDERSTOOD PURSUANT TO ARTICLE 652A OF THE SWISS CODE OF OBLIGATIONS, AND NEITHER THE AGREEMENT NOR ANY OTHER MATERIALS RELATING TO THE OPTION MAY BE PUBLICLY DISTRIBUTED NOR OTHERWISE MADE PUBLICLY AVAILABLE IN SWITZERLAND. 

   

  8

  

   

  ATTACHMENT II 

   

  2019 EQUITY INCENTIVE PLAN

   

  1

  

   

  ATTACHMENT III 

  NOTICE OF EXERCISE

   

  MIRUM PHARMACEUTICALS, INC.

   

  Date of Exercise: _______________

   

  This constitutes notice to Mirum Pharmaceuticals, Inc. (the "Company") under my stock option that I elect to purchase the below number of shares of Common Stock of the Company (the "Shares") for the price set forth below. 

   

  				
	Type of option:
	 
	Nonstatutory

	Stock option dated:
	 
	 

	Number of Shares as
	 
	 

	to which option is
	 
	 
	 

	exercised:
	 
	 

	Certificates to be
	 
	 
	 

	issued in name of:
	 
	 

	Total exercise price:
	 
	US$
	 

	Cash payment delivered
	 
	 

	herewith:
	 
	US$
	 

	[Value of _________ Shares 
	 
	 
	 

	delivered herewith1:
	 
	US$
	______________]

	[Value of _________ Shares
	 
	 
	 

	pursuant to net exercise2:
	US$
	______________]

	[Regulation T Program (cashless exercise3):
	US$
	______________]

   

  1 Shares must meet the public trading requirements set forth in the option.  Shares must be valued in accordance with the terms of the option being exercised, and must be owned free and clear of any liens, claims, encumbrances or security interests.  Certificates must be endorsed or accompanied by an executed assignment separate from certificate. 

  2 The option must be a Nonstatutory Stock Option, and the Company must have established net exercise procedures at the time of exercise, in order to utilize this payment method. 

  3 Shares must meet the public trading requirements set forth in the option.   

  By this exercise, I agree (i) to provide such additional documents as you may require pursuant to the terms of the Mirum Pharmaceuticals, Inc. 2019 Equity Incentive Plan,  and (ii) to provide for the payment by me to you (in the manner designated by you) of the withholding obligation, if any, relating to the exercise of this option. 

   

  	
	Very truly yours,

	 

	 

	 

   

  1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00341-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00341-of-00352.parquet"}]]